Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.

https://www.globenewswire.com/news-release/2022/03/10/2400983/0/en/Zealand-Pharma-Significant-Advancement-of-Clinical-Pipeline-and-Building-Commercial-Momentum-Key-Data-for-Glepaglutide-and-Dasiglucagon-Programs-Expected-in-2022.html

company announcement